Sanofi makes $470M move for Vigil's Alzheimer's drug, while another asset...
Sanofi plans to buy Vigil Neuroscience, a drugmaker advancing TREM2 agonism programs that derive from Amgen. The French pharma will acquire Vigil for its oral small molecule TREM2 project, dubbed...
View ArticleSelf-guided mental health apps can improve outcomes and lower costs: report
As the need for mental health treatment continues to grow, self-guided programs and digital therapeutics can lower spending and improve outcomes, a new report has found. The assessment, conducted by...
View ArticleSamsung Biologics to separate manufacturing and biosimilar businesses
Samsung Biologics is splitting apart its contract manufacturing and biosimilar development activities in a bid to enhance their competitiveness. Samsung Bio will become a pure-play CDMO while a new...
View ArticlePost-Hoc: AI bio needs to heed the overhyped history of CRISPR
John Evans can now reminisce about the days of unrealistic expectations. As CEO of the gene editing biotech Beam Therapeutics, Evans remembers when CRISPR buzz was at its apex, fielding questions at...
View ArticleEndpoints News is getting a new web address https://endpoints.news
Endpoints News is moving to a new website domain on June 1, 2025. The front door is now at: https://endpoints.news The goal is a seamless transition to a URL that is an exact match to our brand. If you...
View ArticleAn unpredictable year for healthcare
Every year, the venture firm Venrock conducts its annual “Healthcare Prognosis” survey that gauges how nearly 300 people across the healthcare industry feel about what’s ahead. This year, Venrock gave ...
View ArticlePharma companies consider 'first sale' rule to ease tariff impact
A little-known — but legal — trade principle is likely to be on pharma companies’ radars as they search for strategies to reduce exposure to President Donald Trump’s planned tariffs on the industry....
View ArticleThe ‘MAHA report’: What it says about vaccines, medicine and the pharma industry
The White House released its MAHA commission report, detailing some of the Trump administration’s top priorities for revamping the US healthcare system and issuing a “call to action.” The 69-page...
View ArticleFDA names acting head of inspections; J&J again advocates for tax policies as...
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. The FDA has selected Elizabeth Miller as its acting associate...
View ArticleCigna, Novo Nordisk offer lower GLP-1 prices
The sun is setting on compounding pharmacies’ ability to make copies of hot weight loss drugs. Pharmacy benefit managers, drugmakers and telehealth companies are lowering their costs to bring patients...
View ArticleHinge Health popped as the digital health IPO market reawakens
Hinge Health ended its first day of trading with shares {$HNGE} up 18%, setting the tone for digital health after a drought of IPOs in the sector. Shares of the virtual physical therapy service started...
View ArticleMakary to senators: FDA staff cuts won't delay user fee targets
FDA Commissioner Marty Makary defended thousands of staff cuts during his first congressional hearing since taking office, seeking to reassure senators that review timelines for new drugs and devices...
View ArticleHouse passes Trump tax bill with PBM and orphan drug reforms included
The House of Representatives on Thursday morning passed President Donald Trump’s tax cut package, with steep Medicaid cuts, PBM reforms and changes to the government's drug price negotiation program...
View ArticleFDA vaccine advisors update Covid strain guidance following new framework
Almost three years ago, Vinay Prasad called a meeting of FDA vaccine advisors a “show trial.” On Thursday, as the director of the FDA center that regulates vaccines, he struck a ...
View Article#ASCO25: Jazz outlines full survival data for lung cancer drug Zepzelca
A drug from Jazz Pharmaceuticals that has yet to read out confirmatory data in lung cancer succeeded in another Phase 3 trial, as the company is slated to present overall survival data at the American ...
View Article#ASCO25: Roche confirms OS benefit for PI3K inhibitor Itovebi in breast cancer
The final overall survival results are in for Roche’s PI3K inhibitor, known as Itovebi, in certain forms of breast cancer. And they bode well for the company and patients. After a median 34.2 months of...
View ArticleGSK’s Nucala wins COPD approval, stoking rivalry with Dupixent
GSK’s blockbuster respiratory drug Nucala was approved Thursday for certain patients with chronic obstructive pulmonary disease, setting up a showdown with Sanofi and Regeneron’s Dupixent. The label...
View Article#ASCO25: Merus’ Phase 2 overall survival data reach ‘home run’ scenario —...
Merus completed its rollout of Phase 2 head and neck cancer data on Thursday, touting overall survival results that at least one analyst said amount to a best-case outcome. In the trial, patients got...
View Article#ASCO25: Volastra unveils first human data of its oral KIF18A drug
Volastra Therapeutics has been bullish about KIF18A as a solid tumor drug target. And now, more than five years after launch, the company is reporting first human data from its in-house drug, VLS-1488....
View ArticleGeoffrey Porges exits Schrödinger with CFO swap; A new board seat for...
Geoffrey Porges, a longtime biotech analyst and well-known Wall Street figure, stepped down as CFO of the New York biotech Schrödinger. Porges spent about two decades covering biopharma as ...
View Article